Neurology News

An international team of investigators has identified a drug candidate that nearly doubles survival rates for patients with diffuse midline glioma, an aggressive type of childhood brain tumor.

A study published recently in Nature found that hyperbaric oxygen therapy led to positive results for cognition and functionality for those with long COVID.

Vigil Neuroscience Inc. has announced positive interim data from a phase 2 proof-of-concept clinical trial of a monoclonal antibody to treat those suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Sleep disorders including insomnia, poor sleep quality and short and long sleep duration were associated with physical frailty among middle-aged and older patients with HIV, researchers found.

A South Korea-based life sciences company has announced expansion into the European Union, United Kingdom, Korea and China of its phase 3 study of an oral, investigational PDE5 inhibitor to treat early Alzheimer’s disease.

Treatment with 100 mg ubrogepant was effective at curbing migraine attacks when administered during the prodromal phase compared with placebo, according to research from The Lancet.

Long-term treatment with psychedelics holds the potential to transform the health care industry through millions in savings, according to an expert at a congressional briefing hosted by Johns Hopkins University.

SAN DIEGO — Approximately two-thirds of patients with ANCA-associated vasculitis report having neurological involvement, according to data presented at ACR Convergence 2023.

Positive results from a pivotal phase 2b trial showed mirdametinib significantly improved the outcomes of patients with neurofibromatosis type 1-associated plexiform neurofibromas, SpringWorks Therapeutics announced in a press release.

Octave Bioscience Inc. has received a $10M grant from the Michael J. Fox Foundation for Parkinson’s Research to advance a custom protein biomarker panel to clinically measure Parkinson’s disease activity and progression.